Loading viewer...
investor_presentation
Format: PDF investor_presentation
© 2021 Tonix Pharmaceuticals Holding Corp.1 September 2021Investor Presentation NASDAQ:TNXP Version P0318 9-7 -2021 (Doc 0892)
© 2021 Tonix Pharmaceuticals Holding Corp.1
September 2021Investor Presentation
Version P0318 9-7 -2021 (Doc 0892)© 2021 Tonix Pharmaceuticals Holding Corp.2Cautionary Note on Forward -Looking
Certain statements inthispresentation regarding strategic plans, expectations andobjectives forfuture
operations orresults are“forward -looking statements” asdefined bythePrivate Securities Litigation Reform
Actof1995.These statements may beidentified bytheuseofforward -looking words such as“anticipate,”
“believe,” “forecast,” “estimate” and“intend,” among others .These forward -looking statements arebased on
Tonix’s current expectations andactual results could differ materially .There areanumber offactors that
could cause actual events todiffer materially from those indicated bysuch forward -looking statements. These
factors include, butarenotlimited to,risks related tofailure toobtain U.S.Food andDrug Administration
clearances orapprovals andnoncompliance withitsregulations ;ourneed foradditional financing ;delays and
uncertainties caused bytheglobal COVID -19pandemic; substantial competition ;uncertainties ofpatent
protection andlitigation ;uncertainties ofgovernment orthird party payor reimbursement ;limited research
anddevelopment efforts anddependence upon third parties .Aswithanypharmaceutical under development,
there aresignificant risks inthedevelopment, regulatory approval andcommercialization ofnewproducts .
Theforward -looking statements inthispresentation aremade asofthedate ofthispresentation, even if
subsequently made available byTonix onitswebsite orotherwise .Tonix does notundertake anobligation to
update orrevise anyforward -looking statement, except asrequired bylaw.Investors should read therisk
factors setforth intheAnnual Report onForm 10-Kfortheyearended December 31,2020,asfiledwiththe
Securities andExchange Commission (the“SEC”) onMarch 15,2021, andperiodic reports andcurrent reports
filed with theSEConorafter thedate thereof .AllofTonix's forward -looking statements areexpressly
qualified byallsuch riskfactors andother cautionary statements .© 2021 Tonix Pharmaceuticals Holding Corp.3Tonix Pharmaceuticals: Who We Are and
Clinical -stage biopharmaceutical company that invents, licenses, acquires and develops
innovative medicines to help patients manage central nervous system (CNS) and immunology
“Advancing science to improve patient care and public health”
Team of passionate professionals
Advancing innovative programs into the clinic: Phase 2 and Phase 3 clinical data are perceived
as value -creating inflection points
Development stage: programs range from preclinical to mid- Phase 3; expect three new
programs in Phase 2 by YE 2021
Preview truncated — download the full document for the complete content.
investor_presentation
48 Pages
investor_presentation
25 Pages
Docebo
investor_presentation
SK Telecom Co
investor_presentation
OneSpan